Comparison of Two Apheresis Systems of COBE and Optia for Autologous Peripheral Blood Stem Cell Collection
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Peripheral blood stem cell (PBSC) transplantation following myeloablative therapy is a mainstay of treatment for various types of malignancies. This study aimed to evaluate the differences between the Optia MNC and COBE Spectra MNC systems (Terumo BCT, Japan) according to apheresis procedures and the parameters of apheresis, products, and collection. The clinical data of 74 patients who underwent autologous PBSC collection from July 2012 to July 2015 were reviewed retrospectively. The patients comprised 48 (65%) men and 26 (35%) women with a median age of 56 yr (range, 23–66 yr). Of 216 procedures, 111 (51%) and 105 (49%) were processed by using COBE and Optia MNC, respectively. PBSC collection rates, throughput, numbers of stem cells retrieved, collection efficacy, and platelet loss were compared. There were no significant differences in the median CD34+ cell counts of collected products (0.61×108 vs 0.94×108), CD34 collection efficiency (43.5% vs 42.1%), and loss of platelets (40.1% vs 44.7%). The Spectra Optia MNC apheresis system was comparable to the COBE Spectra system in collecting autologous CD34+ hematopoietic stem cells and retention of platelets.
Abstract
Peripheral blood stem cell (PBSC) transplantation following myeloablative therapy is a mainstay of treatment for various types of malignancies. This study aimed to evaluate the differences between the Optia MNC and COBE Spectra MNC systems (Terumo BCT, Japan) according to apheresis procedures and the parameters of apheresis, products, and collection. The clinical data of 74 patients who underwent autologous PBSC collection from July 2012 to July 2015 were reviewed retrospectively. The patients comprised 48 (65%) men and 26 (35%) women with a median age of 56 yr (range, 23–66 yr). Of 216 procedures, 111 (51%) and 105 (49%) were processed by using COBE and Optia MNC, respectively. PBSC collection rates, throughput, numbers of stem cells retrieved, collection efficacy, and platelet loss were compared. There were no significant differences in the median CD34+ cell counts of collected products (0.61×108 vs 0.94×108), CD34 collection efficiency (43.5% vs 42.1%), and loss of platelets (40.1% vs 44.7%). The Spectra Optia MNC apheresis system was comparable to the COBE Spectra system in collecting autologous CD34+ hematopoietic stem cells and retention of platelets.
참고문헌 (20)
- Barlogie B, "Treatment of multiple myeloma", Blood, 103, pp.20~32 (2004)
- Li DQ, "Gene expression profile analysis of an isogenic tumour metastasis model reveals a functional role for oncogene AF1Q in breast cancer metastasis", Eur J Cancer, 42, pp.3274~3286 (2006)
- Ikeda K, "Collection of MNCs and progenitor cells by two separators for PBPC transplantation: a randomized crossover trial", Transfusion, 43, pp.814~819 (2003)
- Heuft HG, "Inverse relationship between patient peripheral blood CD34+ cell counts and collection efficiency for CD34+ cells in two automated leukapheresis systems", Transfusion, 41, pp.1008~1013 (2001)
- Karafin MS, "Evaluation of the Spectra Optia apheresis system for mononuclear cell (MNC) collection in G-CSF mobilized and nonmobilized healthy donors: results of a multicenter study", J Clin Apher, 29, pp.273~280 (2014)
- Brauninger S, "Allogeneic donor peripheral blood “stem cell” apheresis: prospective comparison of two apheresis systems", Transfusion, 52, pp.1137~1145 (2012)
- "Spectra Optia® Apheresis System"[URL]
- Brauninger S, "Mobilized allogeneic peripheral stem", progenitor cell apheresis with Spectra Optia v.5.0, a novel, automatic interface-controlled apheresis system: results from the first feasibility trial, 2011, pp.101, 237~246
- "COBE® Spectra Apheresis Syetem"[URL]
- Suh C, "Initiation of peripheral blood progenitor cell harvest based on peripheral blood hematopoietic progenitor cell counts enumerated by the Sysmex SE9000", Transfusion, 44, pp.1762~1768 (2004)
- Kim MK, "A randomized comparison of peripheral blood hematopoietic progenitor cell level of 5", mm3 versus 50, J Clin Apher, pp.2007, 22[DOI]
- Lefrère F, "Evaluation of an algorithm based on peripheral blood hematopoietic progenitor cell and CD34+ cell concentrations to optimize peripheral blood progenitor cell collection by apheresis", Transfusion, 47, pp.1851~1857 (2007)
- Keeney M, "Single platform flow cytometric absolute CD34+ cell counts based on the ISHAGE guidelines. International Society of Hematotherapy and Graft Engineering", Cytometry, 34, pp.61~70 (1998)
- Sutherland DR, "Comparison of two single-platform ISHAGE-based CD34 enumeration protocols on BD FACSCalibur and FACSCanto flow cytometers", Cytotherapy, 11, pp.595~605 (2009)
- Ford CD, "Comparison of CD34+ cell collection efficiency on the COBE Spectra and Fenwal CS-3000 Plus", J Clin Apher, 17, pp.17~20 (2002)
- Reinhardt P, "Automatic interface-controlled apheresis collection of stem", progenitor cells: results from an autologous donor validation trial of a novel stem cell apheresis device, 2011, pp.51, 1321~1330
- Long G, "Evaluation of the spectra Optia® mononuclear cell collection procedure in multiple myeloma patients", J Clin Apher, 30, pp.1~7 (2015)
- Flommersfeld S, "A single center comparison between three different apheresis systems for autologous and allogeneic stem cell collections", Transfus Apher Sci, 49, pp.428~433 (2013)
- Lee JS, "Comparison of Amicus and CS-3000 Plus for the collection of peripheral blood stem cells", Korean J Blood Transfus, 17, pp.39~47 (2006)
- Cherqaoui B, "Peripheral blood stem cell collection in low-weight children: retrospective comparison of two apheresis devices", Transfusion, 54, pp.1371~1378 (2014)